MBII: Marrone Bio Innovations announces the results of a next generation nematicide/insecticide, MBI-306.
Byline: Zacks Small Cap Research
By Ian Gilson, PhD, CFA
READ THE FULL MBII RESEARCH REPORT
Field trials of a next generation nematicide/insecticide, designated MBI--306, derived from a soil bacterium discovered by Marrone Bio Innovations (NASDAQ: MBII) showed superior control of insects and nematodes in corn.
Corn is the world's most important grain and U.S. farmers planted over 90 million acres in 2019, about one third of the worldwide production. Only wheat matches corn with wheat being grown over a larger area than corn.
The six trials matched MBI-306 against Majestene (a Marrone Bio product) and current chemical treatments. MBI-306 demonstrated a yield improvement as application rates increased when compared to commercial standards.
The product is in the final phase of R&D and will be submitted for regulatory approval in 2020. Depending on the EPA timeline MBI-306 could enter the market in late 2020 but more probably in 2021.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.
|Printer friendly Cite/link Email Feedback|
|Author:||Zacks Small Cap Research|
|Article Type:||Financial report|
|Date:||Dec 18, 2019|
|Previous Article:||Powerful Storm Could Delay Christmas Deliveries In Pacific Northwest.|
|Next Article:||Canadian Manufacturing Took Hit During GM Strike.|